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K-Ras is a monomeric GTPase that controls cellular and tissue homeostasis. Prior studies demonstrated that mutationally
activated K-Ras (K-RasG12D) signals through MEK to promote expansion and hyperproliferation of the highly mitotically active
transit-amplifying cells (TACs) in the intestinal crypt. Its effect on normally quiescent stem cells was unknown, however. Here,
we have used an H2B-Egfp transgenic system to demonstrate that K-RasG12D accelerates the proliferative kinetics of quiescent
intestinal stem cells. As in the TAC compartment, the effect of mutant K-Ras on the quiescent stem cell is dependent upon
activation of MEK. Mutant K-Ras is also able to increase self-renewal potential of intestinal stem cells following damage. These
results demonstrate that mutant K-Ras can influence intestinal homeostasis on multiple levels.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Abbreviations: DOX, doxycycline; Egfp, enhanced green
fluorescent protein; TACs, transit amplifying cells
☆ Funding: This work was supported by a Research Scholar Grant
from the American Cancer Society (MGO-114877 to K.M.H.) and by
grants from the National Institutes of Health (5R01CA151566 to
K.M.H., 5R01CA084056 to D.T.B., 5P30HD18655 to the Children's
Hospital Intellectual and Developmental Disabilities Research Center,
and 5P30DK034854 to the Harvard Digestive Disease Center). J.J.G. is
supported by a postdoctoral fellowship, PF-13-081-01-TBG, from the
American Cancer Society.
☆☆ Author contributions: K.M.H., J.J.G., and D.T.B. designed
the study; J.J.G., J.L., M.S.S., and C.G. acquired the data;
K.M.H., J.J.G., J.L., and C.G. analyzed and interpreted the data;
and K.M.H. and J.J.G. wrote the manuscript.
⁎ Corresponding author at: Beth Israel Deaconess Medical Center,
3 Blackfan Circle, CLS Building Room 409, Boston, MA 02215, USA.
E-mail address: khaigis@bidmc.harvard.edu (K.M. Haigis).
http://dx.doi.org/10.1016/j.scr.2015.06.003
1873-5061/© 2015 The Authors. Published by Elsevier B.V. This is an ope
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4Introduction
Homeostasis in the intestinal epithelium requires the concert-
ed action of multiple stem and progenitor populations. Some of
these populations are highly proliferative, while others are
typically quiescent (Barker, 2014). Highly-proliferative, or
fast-cycling, stem cells are present throughout the intestine
and are responsible for the daily maintenance of the
epithelium, and therefore represent the “work-horse” for
intestinal homeostasis (Barker et al., 2007). Slowly-cycling, or
quiescent, stem cells are less prevalent and have been shown
to be able to replace fast-cycling stem cells after injury, and
therefore are considered clonogenic reserve cells that can
maintain intestinal homeostasis (Buczacki et al., 2013; Tian et
al., 2011). While the precise relationships between then access article under the
.0/).
166 J.J. Gierut et al.different types of stem and progenitor cells remain to be
determined, it is clear that altering their growth properties can
lead to pathology, for example cancer (Barker et al., 2009).
We demonstrated previously that activation of the K-Ras
oncoprotein promotes expansion and hyper-proliferation with-
in the intestinal transit amplifying cells (TACs), a population
that is normally highly proliferative (Haigis et al., 2008).
Similarly, oncogenic K-Ras has been shown to accelerate the
rate of cell division in Lgr5+ stem cells in the small intestine
(Snippert et al., 2014). Here, we have studied if/how mutant
K-Ras can affect the proliferative and self-renewal properties
of intestinal stem cells that are normally quiescent.Material and methods
Animals and tissues
All mice were cared for according to the guidelines of the
Hospital Subcommittee on Animal Research (SRAC). Fabpl-Cre;
K-RasLSL-G12D/+ animals have been described previously
(Haigis et al., 2008). In these animals, Cre is expressed only in
the distal small intestinal and colonic epithelia, so mutant
K-Ras is expressed only in those regions. Rosa26-M2-rtTA;
ColA1-H2B-Egfp transgenicmice have been described previously
(Foudi et al., 2009). In this system, the M2 reverse tetracycline
transactivator (M2-rtTA) is knocked into the Rosa26 locus, which
is expressed in all cells in the adult mouse. Expression of the
H2B-Egfp chimeric cDNA from the collagen 1a1 locus is
regulated by a doxycycline (DOX) response element. In the
absence of DOX, the H2B-Egfp fusion protein is not expressed.
When animals are administered with DOX in the drinking water,
M2-rtTA binds to the response element and induces expression
of H2B-Egfp. Both control (Fabpl-Cre; Rosa26-M2-rtTA;
ColA1-H2B-Egfp) and K-Ras mutant (Fabpl-Cre; K-RasLSL-G12D;
Rosa26-M2-rtTA; ColA1-H2B-Egfp) animals (4–6 week old mice
at the beginning of treatment) were given a pulse of DOX
(Sigma-Aldrich, 2 mg/ml in water) in the drinking water for
2 weeks. DOX was then removed from the drinking water and
animals were sacrificed at defined time points: 1, 3, 5, 7, 9,10,
11, 13, 15, 20, and 25 days. At least 3 animals were analyzed at
each time point following DOX removal.
Control and K-Ras mutant animals that were treated with
PD0325901 were also given a 2 week pulse of DOX in the
drinking water. Following removal of DOX, animals were given
a daily intraperitoneal injection of PD0325901 (ChemieTek,
12.5 mg/kg in 10% DMSO) or 10% Dimethyl Sulfoxide (DMSO)
and then sacrificed at defined time points: 5, 7, and 13 days.
Five animals were analyzed at each time point.
For experiments in which dextran sodium sulfate (DSS)
was used to induce epithelial damage, percent damage was
determined by dividing the summed length of all damaged
regions by the total length of the distal colon. Damaged
tissue was defined as any region that was not healthy.
Healthy tissue was taken to be any contiguous region that
had at least 5 undamaged crypts. For all animals, distal
colon was taken to be 5 cm of colon from the distal end.
For tissue collection, animals were sacrificed and the entire
intestinal tract was removed and washed with cold PBS. For
immunohistochemical analysis, tissues were fixed in formalin
overnight. For western blot analysis tissue was lysed in RIPA
buffer and stored at −80°C. The proximal small intestine(duodenum) was obtained from tissue immediately adjacent to
the stomach. The distal small intestine (ileum) was obtained
from tissue immediately adjacent to the cecum. The colon was
obtained from tissue immediately adjacent to the rectum.
Flow cytometry, RNA preparation, and qRT-PCR
Rosa26-M2-rtTA; ColA1-H2B-Egfp transgenic mice were given
a pulse of doxycycline in the drinking water for 2 weeks. DOX
was then removed from the drinking water and animals were
sacrificed at 25 days post induction. Lgr5-Egfp-IRES-CreERT2
mice were 8–10 weeks of age. Following sacrifice, colons
were removed, opened longitudinally and cut into 3-5 mm
segments. Tissue was placed in cold PBS (Ca and Mg-free)
and vortexed 6 times for 5 s to remove debris and fecal
matter before incubation in PBS with 20 mM EDTA at 37 °C
for 30 min. The tissue was then transferred to cold PBS and
vortexed vigorously to release the crypts. Crypt-containing
supernatants were supplemented with 10% FBS, pelleted and
resuspended in DMEM for one additional wash. Following
spin, crypt pellet was resuspended in 10 ml TrypLE Express
(Invitrogen #12605-010) with DNase (1000 u/10 ml, Sigma
#D5025), and incubated at 37 °C for 45 min with intermit-
tent mixing to disassociate the crypts into single cells. Cells
were filtered through a 40 μm cell strainer (BD Bioscience
#352340) into DMEM (Corning #10-013-CV) media containing
5 mM EDTA. Cells were washed twice with DMEM and
resuspended in DMEM with 4 mM MgCl2, 200 u/ml DNase,
and Propidium Iodide. Because H2B-Egfp animals also show
expression of Egfp in immune cells, cells from those animals
were stained with CD45-APC-Cy7 (Biolegend #103116) for
10 min at room temperature before resuspension in sorting
media. Using the BD Aria flow cytometer, cells were gated
on PI negative, CD45 negative populations and then the high
Egfp expressing populations (~2% total epithelial cells) and
Egfp negative populations were sorted directly into TRIzol.
RNA was isolated using TRIzol reagent according to
manufacturer's instructions. Subsequently, cDNA was made
using High Capacity cDNA Reverse Transcriptase kit (Applied
Biosystems) and quantitative real time PCR was performed
using TaqMan PCR assays (Applied Biosystems) to detect
the expression of Egfp (Assay ID: Mr04097229-mr), Leucine-
richrepeat-containing G-protein coupled receptor 5 (Lgr5,
Mm00438890_m1), Olfactomedin 4 (Olfm4, Mm01320260_m1),
Achaete-scute complex homolog 2 (Ascl2, Mm01268891_g1),
Axin 2 (Mm00443610_m1), Mucin 2 (Muc2, Mm01276696_m1),
Alkaline phosphatase (Alph, Mm01285814_g1), and Chromo-
granin A (Chga, Mm00514341_m1). All samples were run in
duplicate and normalization was carried out using the 2ΔΔCT
method relative to 18S rRNA (Mm03928990).
Immunohistochemistry
Tissues were processed for histology via standard protocols and
tissue sections were cut to 5 μm. Tissue sections were stained
with mouse anti-GFP antibody (Clontech, 632380), rabbit
anti-phospho-Histone H3 antibody (Ser10, #9701), and the
Vectastain ABC Kit (Vector Laboratories) according to
manufacturer's instructions. Reactions were visualized with
3,3′-diaminobenzidine (DAB) and counterstained with
hematoxylin.
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Polyacrylamide gels (10%) were loaded with 40 μg of mouse
epithelial intestinal protein. Immunoblotting was performed
using rabbit anti-Erk1/2 (Cell Signaling Technology #4696),
mouse anti-phospho-Erk1/2 (Cell Signaling Technology
#9101), and mouse anti-α-Tubulin (Sigma-Aldrich #T6074).
Membranes were incubated with primary antibodies over-
night at 4 °C and incubated for 1 h at room temperature
with secondary antibodies (Rockland) diluted at 1:10,000.
Membranes were scanned using a LI-COR Odyssey infrared
imaging system.Statistical analysis
The ratio qRT-PCR values depicted in Fig. 1C was computed
for the ith animal as θi/αi, where θi was the Egfp + qRT-PCR
signal and αi was the Egfp-qRT-PCR signal. Ratios were
averaged over i = [1,2,3] (N = 3 animals), then log2 trans-
formed. Error bars represent mean ± SEM of the log2
transformed values. A signal was considered to be enriched
if its log2 transformed values were significantly greater than
0 (corresponding to ratio values greater than 1). Statistical
significance was computed on the log2 transformed valuesfor each quantified gene using a one-sample t-test
(GraphPad Prism 6). Egfp half-life in Fig. 2 was calculated
using a sigmoidal dose–response curve with variable slope
(Prism). Statistical significance between half-life for each
experimental group (control/K-Ras) was assessed from the
mean ± SE values for the logEC50 (half-life). The logEC50s
were compared using the F-test (GraphPad Prism 6) to assess
significance. Statistical significance for the DSS-induced
damage data presented in Fig. 3D was assessed from the
mean ± SE values for each group (Graphpad Prism 6). A
two-tailed t-test was used to determine the P-value.
Results
Quiescent cells can be identified in vivo by virtue of their ability
to retain label. Historically, this was achieved by treating
animals with nucleotide analogues, for example 5-bromo-2′-
deoxyuridine (BrdU) or tritiated thymidine, that are incorpo-
rated into DNA during replication (Morris & Potten, 1994). More
recently, transgenic systems have been developed in which
enhanced green fluorescent protein (Egfp)-labeled histones are
inducibly expressed and then incorporated into chromatin
(Tumbar et al., 2004). We utilized a mouse strain that allows
for ubiquitous, doxycycline (DOX)-inducible expression of an
H2B-Egfp fusion protein (Foudi et al., 2009) (Fig. 1A). Immedi-
ately following a pulse of DOX, the entire intestinal epithelium
is Egfp-positive. As the cells at the base of the crypt divide and
migrate up toward the lumen, Egfp signal is progressively
diluted. Within a short period of time, around 25 days, a single
Egfp-positive cell typically remains near the bottom of the crypt
(Fig. 1B).Figure 1 H2B-Egfp label retention in the intestinal epithelium.
(A) Schematic representation of the label retention time course.
Rosa26-M2-rtTA; ColA1-H2B-Egfp transgenic mice have been
described previously (Foudi et al., 2009). In this system, the M2
reverse tetracycline transactivator (M2-rtTA) is knocked into the
Rosa26 locus, which is expressed in all cells in the adult mouse.
Expression of the H2B-Egfp chimeric protein from the collagen 1a1
locus is regulated by a doxycycline response element. In the
absence of DOX, H2B-Egfp is not expressed. When animals are
administered DOX in the drinking water, M2-rtTA binds to
the response element and induces expression of H2B-Egfp.
(B) Immunohistochemistry for Egfp over the time course of the
labeling experiment. Over time, only a single Egfp-positive cell
remains at the bottom of the crypt, which is the slowly cycling
stem cell (red arrow). Egfp immunohistochemistry is shown for
crypts in the distal colon. (C) qRT-PCR data comparing expression
patterns of stem cell markers in putative Egfp+ stem cells. In Egfp+
colonic epithelial cells from both Rosa26-M2-rtTA-ColA1-H2B-Egfp
and Lgr5-Egfp-IRES-CreERT2 mice, there is a 3–4 fold enrichment
of stem cell markers and a negative enrichment of differentiation
markers. The qRT-PCR ratio values were computed as the
normalized qRT-PCR signal from Egfp + cells divided by the
normalized qRT-PCR signal Egfp− cells from the same animal.
Ratios were averaged (N = 3 animals), then log2 transformed.
Error bars represent +/− SEM values for each group. Statistical
significance of each gene was computed using a one sample t-test
of the log2 transformed ratio values relative to 0 (see Section 2).
* represents P = 0.01, ** represents P b 0.01.
Figure 2 K-RasG12D accelerates the loss of Egfp label in the intestinal epithelium. (A–C) Determination of Egfp half-life in animals
expressing WT or mutant K-Ras. Animals were exposed to DOX (2 mg/ml) in the drinking water for 2 weeks and then sacrificed at
defined time points. Immunohistochemistry for Egfp was used to identify crypts that included at least a single Egfp+ cell. Using these
data, the Egfp half-life for control (black line) and K-Ras mutant animals (gray dotted line) was determined for the proximal small
intestine (A), distal small intestine (B) and colon (C). A minimum of 3 animals were used for each experimental group at each time
point, with approximately 50 crypts analyzed per animal. The Egfp half-life was significantly reduced by K-RasG12D in the distal small
intestine (P = 0.0212) and colon (P = 0.0002), but not in the proximal small intestine (P = 0.3510). (D) Position of Egfp label-retaining
cells in WT and mutant animals. At time points near the half-life for each condition, immunohistochemistry for Egfp was used to
determine the relative positions of Egfp+ cells within crypts that contain a single labeled cell. A minimum of 200 crypts was counted
for each experimental group. Both experimental groups illustrated a similar distribution of Egfp positive cells within the crypt.
(E) Distribution of mitotic cells in WT and mutant animals. The relative positions of phospho-Histone H3 (PH3) positive cells within
crypts was determined by immunohistochemistry for PH3. A minimum of 200 cells at each position were counted for each
experimental group. K-Ras mutant animals (gray line) displayed a higher percentage of PH3-positive mitotic cells than control animals
(black line), particularly at cell position 1–5, were stem cells reside. (F–H) Determination of Egfp half-life after MEK inhibition in
animals expressing WT or mutant K-Ras. Animals were treated daily with PD0325901 (MEKi) for either 5, 7, or 13 days following DOX
pulse. The half-life for both control (black line) and K-Ras mutant animals (gray dotted line) was determined for the proximal small
intestine (F), distal small intestine (G) and colon (H). 5 animals per time point were used for each experimental group. In the
presence of MEKi, K-RasG12D does not affect label retention.
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stem cells, we used qRT-PCR to measure the expression of both
stem cell (Lgr5, Olmf4, Ascl2, and Axin2) and differentiation
markers (Muc2, Alph, and Chga) in epithelial cells isolated from
Rosa26-M2-rtTA; ColA1-H2B-Egfp animals 25 days post DOX
induction. Egfp+ epithelial cells from these animals wereenriched for stem cell markers relative to Egfp− epithelial
cells, while the Egfp− cells were enriched for markers of
differentiation (Fig. 1C). As a control, we performed the same
experiment on Lgr5-Egfp-IRES-CreERT2 mice, where the Egfp+
cells represent bona fide intestinal epithelial stem cells. In
these animals, as in the Rosa26-M2-rtTA; ColA1-H2B-Egfp
Figure 3 K-RasG12D animals recover more efficiently from DSS-induced damage than control animals. (A) Mouse body weight
changes following treatment with 3% DSS (6 days). Both experimental groups (WT, K-RasG12D) lose weight over the course of
treatment, with animals expressing K-RasG12D losing slightly less weight. (B) Mouse body weight changes following treatment with 3%
DSS (6 days) followed by water (6 days). Both experimental groups (WT/K-Ras) lose weight over the course of treatment. (C)
Hematoxylin and eosin staining of the colonic epithelium from control (WT) and K-Ras mutant animals following treatment with 3%
DSS (6 days) followed by water (6 days). The epithelial damage is restricted to the distal colon (black box), which is magnified in the
panels on the right. (D) Quantification of histological damage following DSS treatment (DSS). The damage was significantly reduced in
K-RasG12D mutant animals both immediately after DSS exposure (P = 0.01) and following recovery from injury (P = 0.002).
169Oncogenic K-Ras promotes proliferation in quiescent intestinal stem cellsanimals, Egfp+ epithelial cells were enriched for stem cell
markers (Fig. 1C). These data indicate that the isolated label
retaining cells present at the bases of the crypts of
Rosa26-M2-rtTA; ColA1-H2B-Egfp animals 25 days after DOX
stimulation are indeed intestinal stem cells.
In order to determine whether mutant K-Ras (K-RasG12D)
affects label retention, we crossedmice carrying the inducible
histone H2B-Egfp transgene to animals expressing K-RasG12D in
the distal small intestinal and colonic epithelia (Haigis et al.,
2008). Both control and K-Rasmutant animals were exposed to
DOX in the drinking water for 14 days to ensure that all cells of
the colonic epithelium were labeled. After this initial pulse,
DOX was removed from the drinking water and intestinal
epithelia were analyzed at different time points in order to
detect cells that retained the H2B-Egfp label. Egfp-positive
epithelial cells were quantified and tabulated as the number
of positive cells per crypt. These experiments were used to
determine the “half-life” of the H2B-Egfp label in both control
and K-RasG12D epithelium, which we defined as the time-point
at which 50% of the colonic crypts retain at least a single
labeled cell. As expected, control and mutant animals
illustrated little difference in Egfp half-life at the proximalsmall intestine, since K-RasG12D is expressed only in the distal
small intestine and colon (Fig. 2A). By contrast, the retention
of label was significantly different between control and
mutant animals in the distal small intestinal (a half-life
difference of 1.2 days) and colonic epithelia (a half-life
difference of 3.7 days), with K-RasG12D tissues exhibiting a
significantly reduced Egfp half-life (Fig. 2B,C). While muta-
tional activation of K-Ras altered the kinetics of label
retention in the colonic epithelium, it did not alter the
distribution of Egfp+ cells, the majority of which were found in
positions 1–5 at the bottom of the crypt (Fig. 2D). Consistent
with the idea that mutant K-Ras alters the kinetics of label
retention through its effect on proliferation, animals express-
ing K-RasG12D exhibited an increased frequency of mitotic
stem cells relative to controls (Fig. 2E). Taken together, these
data indicate that K-RasG12D promotes hyperproliferation of
normally quiescent intestinal stem cells.
In our prior studies, we showed that K-RasG12D promotes
proliferation in the intestinal epithelium by activating MEK,
but that K-RasG12D promotes proliferation of colorectal
cancer cells through a MEK-independent mechanism (Haigis
et al., 2008). To determine whether K-RasG12D promotes
170 J.J. Gierut et al.quiescent stem cell proliferation through a MEK-dependent
or -independent mechanism, we treated control and mutant
animals with PD0325901, an orally active MEK inhibitor
(MEKi), (Bain et al., 2007) and then repeated label retention
studies. Our pilot experiments indicated that PD0325901 was
highly effective in suppressing MEK activity in vivo in the
colonic epithelium (Supplemental Fig. 1). Similar to what we
observed in our initial experiment, control and mutant
animals treated with MEKi did not differ in label retention in
the proximal small intestine (Fig. 2F). By contrast, while
MEK inhibition did not alter label retention in the small
intestine and colon of control animals, MEKi reverted the
K-RasG12D label retention phenotype to that of control
animals (Fig. 2G,H). These data strongly suggest that mutant
K-Ras promotes hyperproliferation of quiescent intestinal
stem cells via a MEK-dependent pathway.
Quiescent intestinal stem cells are also known to play a
central role in mucosal regeneration upon tissue injury
(Potten & Grant, 1998). Following injury induced by
cytotoxic or genotoxic agents, the quiescent stem cells
become mitotically active, leading to restoration of normal
epithelial architecture and barrier function (Roth et al.,
2012). In order to determine whether mutant K-Ras can
affect quiescent stem cells following injury, animals ex-
pressing WT or mutant K-Ras were exposed to 3% dextran
sodium sulfate (DSS) in their drinking water for 6 days and
then sacrificed, or else allowed to recover for 6 days and
then sacrificed. Exposure to DSS induces mucosal injury and
subsequent inflammation in the distal colon of rodents
(Vowinkel et al., 2004). Significant weight loss was evident
in both experimental groups following acute DSS treatment,
although animals expressing K-RasG12D tended to lose less
weight (Fig. 3A,B). To assess whether the weight loss
phenotypes correlated with epithelial damage, we per-
formed a histologic analysis of the colonic epithelium
following DSS exposure. Both groups demonstrated alter-
ations in the epithelial structure, neutrophil and lymphocyte
infiltration into the mucosal and submucosal areas, and
crypt loss (Fig. 3C), with control animals displaying a 1.6 fold
increase in the amount of initial damage in the distal colon
relative to animals expressing K-RasG12D (Fig. 3D). Following
a 5-day recovery from DSS treatment, both experimental
groups exhibited features of tissue repair, with K-Ras mutant
animals exhibiting a more dramatic recovery in epithelial
morphology than animals expressing WT K-Ras (Fig. 3D).
These results suggest that animals expressing mutant K-Ras
are able to recover from epithelial damage more efficiently
than are control animals.Discussion
Proper intestinal homeostasis requires tight regulation of
proliferation in epithelial stem and progenitor cells. Neverthe-
less, the mechanisms controlling cell division in distinct
populations of epithelial cells are not completely deciphered.
We previously demonstrated that mutant K-Ras, a monomeric
GTPase that functions as binary switch to control proliferation,
differentiation, apoptosis, cell adhesion, and cell migration,
increases the proliferative index in TACs (Haigis et al., 2008).
Activating missense mutations are common in cancer and they
impair GTPase activity, locking K-Ras into its GTP-bound(active) state and allowing it to constitutively activate
downstream signaling (Ahearn et al., 2012). Expression of
mutant K-Ras also accelerates the division rates of Lgr5+ stem
cells, leading to clonal expansion of crypts expressing the
oncoprotein (Snippert et al., 2014), suggesting that isolated
mutational activation of K-Ras could lead to field effects prior
to neoplastic initiation. Here, we have found that K-RasG12D also
enhances proliferation of intestinal stem cells that are normally
quiescent. These quiescent cells have been shown to differen-
tiate into Paneth cells and enteroendocrine cells under
homeostatic conditions, and then to give rise to all epithelial
lineages following damage (Buczacki et al., 2013). Interestingly,
small intestinal crypts expressing mutant K-Ras do not develop
Paneth cells (Feng et al., 2011), suggesting that the quiescent
state may be important for maturation into this differentiated
cell type.
Paradoxically, we found that mutant K-Ras increases
proliferation of quiescent intestinal stem cells (Fig. 2), but
also increases repair following damage (Fig. 3). This phenom-
enon is similar to the role that oncogenic N-Ras plays in
hematopoietic stem cells (HSCs) (Li et al., 2013). In this
context, N-RasG12D promotes proliferation and self-renewal of
HSCs. Going forward, it will be interesting to determine if this
“bimodal” response of stem cells to Ras activation is specific
to the Ras family of oncogenes, or whether it is a common
feature of other oncogenic mutations.
In our prior work, we found that mutant K-Ras reprograms
TACs to be entirely dependent upon MEK signaling for
proliferation; inhibition of MEK did not affect proliferation of
wild-type TACs, but K-Ras mutant TACs exhibited almost no
proliferative capacity when exposed to MEKi (Haigis et al.,
2008). Similar to our prior work, we now find that mutant
K-Ras signals through MEK to promote hyperproliferation of
the normally quiescent intestinal stem cell (Fig. 2). In contrast
to our previous studies, however, mutant K-Ras did not
reprogram the quiescent cell to be entirely dependent upon
MEK. Instead, inhibition of MEK in the context of mutant K-Ras
simply restored label retention to that of control animals.
Together, these observations suggest that mutant K-Ras
differentially influences the molecular program controlling
proliferation in distinct epithelial cell types in the intestine.
These observations may be highly relevant to the use of MEK
inhibitors for colorectal cancers expressing mutant K-Ras.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2015.06.003.
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